- Home
- FORA vs DXR Comparison
FORA vs DXR Comparison
Compare FORA & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FORA | DXR |
|---|---|---|
| Founded | 2014 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.3M | 59.0M |
| IPO Year | 2020 | 1995 |
Fundamental Metrics
Financial Performance| Metric | FORA | DXR |
|---|---|---|
| Price | $2.16 | $10.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 39.5K | 6.2K |
| Earning Date | 05-13-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,256,919.00 | $1,446,345.00 |
| Revenue This Year | $8.44 | $44,935.22 |
| Revenue Next Year | N/A | $74.79 |
| P/E Ratio | ★ N/A | $33.83 |
| Revenue Growth | ★ 50.13 | N/A |
| 52 Week Low | $1.64 | $7.47 |
| 52 Week High | $2.71 | $14.76 |
Technical Indicators
Market Signals| Indicator | FORA | DXR |
|---|---|---|
| Relative Strength Index (RSI) | 60.16 | 49.15 |
| Support Level | $2.11 | $9.33 |
| Resistance Level | $2.20 | $11.69 |
| Average True Range (ATR) | 0.01 | 0.79 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 33.33 | 33.79 |
Price Performance
Historical ComparisonAbout FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system.